My watch list
my.bionity.com  
Login  

18-05-2012: Sygnature Discovery Limited and Pneumolabs (UK) Limited announced they have entered into a strategic alliance.  Under the terms of the agreement, Sygnature and Pneumolabs will collaborate to provide a fully-integrated drug discovery service to accelerate clients’ drug discovery programmes into development.  This new alliance complements Sygnature’s existing strategic alliances with Cyprotex Discovery, a centre of excellence for in vitro ADME/toxicology, and Saretius, a pre-clinical experimental services company offering ‘gold standard’ techniques in pain, metabolic and CNS disorders, inflammatory disease and in vivo pharmacokinetics.

Contact / Request information

Request further information free of charge:

Watchlist

This is where you can add this news to your personal favourites

Facts, background information, dossiers
More about Sygnature Discovery
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE